GlassScriptPhysician profile
Jesse W Price
NPI 1093091761
$5,592.24
in general payments reported to CMS, 2019-2025
43 companies · $1,145 in 2025
The $1,145 reported for 2025 was more than what 82% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,742 · 2022: $797 · 2023: $527 · 2024: $1,382 · 2025: $1,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,054.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $662.26 | 2021-2025 | |
| Novo Nordisk INC | $620.60 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $439.45 | 2021-2025 | |
| Amgen INC. | $437.93 | 2021-2025 | Repatha, Evenity, Prolia |
| Lilly USA, LLC | $386.92 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.81 | 2021-2025 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $261.31 | 2021-2024 | Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $206.06 | 2021-2023 | Jardiance |
| Glaxosmithkline, LLC. | $197.55 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $168.76 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.66 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $123.57 | 2021-2025 | Spravato |
| Ardelyx, INC. | $114.30 | 2024 | Ibsrela |
| Esperion Therapeutics, INC. | $112.48 | 2021-2025 | Nexletol |
| Abbott Laboratories | $109.90 | 2022-2025 | Freestyle Libre 3 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Price listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.